Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation - 13/09/23
, Shephal K. Doshi, MD b, #, Mohamad Alkhouli, MD c, A. John Camm, MD d, Megan Coylewright, MD e, Michael C. Gibson, MD f, Christopher B. Granger, MD g, Mahmut E. Gurol, MD h, Kenneth Huber, MD i, Moussa Mansour, MD j, Devi G. Nair, MD k, Andrea Natale, MD l, Stuart J. Pocock, MD m, Vivek R. Reddy, MD n, Walid Saliba, MD o, Thomas Christen, MD, PhD p, Dominic J. Allocco, MD p, Kenneth A. Ellenbogen, MD q, Martin B. Leon, MD rRésumé |
Background |
Percutaneous left atrial appendage (LAA) closure (LAAC) was developed as a nonpharmacologic alternative to oral anticoagulants (OACs) in patients with atrial fibrillation (AF) who are at an increased risk for stroke or systemic embolism. The Watchman device permanently seals off the LAA to prevent thrombi from escaping into the circulation. Previous randomized trials have established the safety and efficacy of LAAC compared to warfarin. However, direct OACs (DOACs) have become the preferred pharmacologic strategy for stroke prevention in patients with AF, and there is limited data comparing Watchman FLX to DOACs in a broad AF patient population. CHAMPION-AF is designed to prospectively determine whether LAAC with Watchman FLX is a reasonable first-line alternative to DOACs in patients with AF who are indicated for OAC therapy.
Study Design |
A total of 3,000 patients with a CHA2DS2-VASc score ≥2 (men) or ≥3 (women) were randomized to Watchman FLX or DOAC in a 1:1 allocation at 142 global clinical sites. Patients in the device arm were to be treated with DOAC and aspirin, DOAC alone, or DAPT for at least 3 months postimplant followed by aspirin or P2Y12 inhibitor for 1-year. Control patients were required to take an approved DOAC for the duration of the trial. Clinical follow-up visits are scheduled at 3- and 12-months, and then annually through 5 years; LAA imaging is required at 4 months in the device group. Two primary end points will be evaluated at 3 years: (1) composite of stroke (ischemic/hemorrhagic), cardiovascular death, and systemic embolism compared for noninferiority, and (2) nonprocedural bleeding (International Society on Thrombosis and Haemostasis [ISTH] major and clinically relevant nonmajor bleeding) tested for superiority in the device arm against DOACs. The third primary noninferiority end point is the composite of ischemic stroke and systemic embolism at 5 years. Secondary end points include 3- and 5-year rates of (1) ISTH-defined major bleeding and (2) the composite of cardiovascular death, all stroke, systemic embolism, and nonprocedural ISTH bleeding.
Conclusions |
This study will prospectively evaluate whether LAAC with the Watchman FLX device is a reasonable alternative to DOACs in patients with AF.
Clinical Trial Registration |
NCT04394546
Le texte complet de cet article est disponible en PDF.Plan
Vol 264
P. 123-132 - octobre 2023 Retour au numéro
Article précédent
- Near-infrared spectroscopy-intravascular ultrasound to improve assessment of coronary artery disease severity in patients referred for transcatheter aortic valve implantation (The IMPACTavi registry): Design and rationale
- Masaru Seguchi, Alp Aytekin, Lena Steiger, Philipp Nicol, Costanza Pellegrini, Tobias Rheude, Leif-Christopher Engel, Hector A. Alvarez‐Covarrubias, Erion Xhepa, N. Patrick Mayr, Martin Hadamitzky, Adnan Kastrati, Heribert Schunkert, Michael Joner, Tobias Lenz
- The left atrial appendage closure by surgery-2 (LAACS-2) trial protocol rationale and design of a randomized multicenter trial investigating if left atrial appendage closure prevents stroke in patients undergoing open-heart surgery irrespective of preoperative atrial fibrillation status and stroke risk
- Christoffer Læssøe Madsen, Jesper Park-Hansen, Akhmadjon Irmukhamedov, Christian Lildal Carranza, Sulman Rafiq, Rafael Rodriguez-Lecoq, Neiser Palmer-Camino, Ivy Susanne Modrau, Emma C. Hansson, Anders Jeppsson, Rakin Hadad, Angel Moya-Mitjans, Anders Møller Greve, Robin Christensen, Helle Gervig Carstensen, Nis Baun Høst, Ulrik Dixen, Christian Torp-Pedersen, Lars Køber, Ismail Gögenur, Thomas Clement Truelsen, Christina Kruuse, Ahmad Sajadieh, Helena Domínguez, LAACS-2 trial Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?